ERBB2 and triple-negative breast carcinoma: Among these, 108 were patients with triple-negative breast cancer (TNBC) who had received at least two prior anticancer treatments for metastatic TNBC, and 54 patients had HR+/HER2-metastatic breast cancer, having received a minimum of two prior metastatic breast cancer treatments.